{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:42Z","timestamp":1762876002437},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10557-018-6817-7","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T03:37:23Z","timestamp":1533181043000},"page":"365-372","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies"],"prefix":"10.1007","volume":"32","author":[{"given":"Leslie","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ruzza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Flower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"2","key":"6817_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","volume":"104","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109\u201324.","journal-title":"QJM"},{"issue":"14","key":"6817_CR2","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Raber L, Mach F, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172\u201380.","journal-title":"Eur Heart J"},{"issue":"1","key":"6817_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","volume":"168","author":"HV Ganga","year":"2014","unstructured":"Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6\u201315.","journal-title":"Am Heart J"},{"key":"6817_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.phrs.2017.09.013","volume":"128","author":"JC Irwin","year":"2018","unstructured":"Irwin JC, Khalesi S, Fenning AS, Vella RK. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: a systematic review and meta-analysis. Pharmacol Res. 2018;128:264\u201373.","journal-title":"Pharmacol Res"},{"issue":"6","key":"6817_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"6817_CR6","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","volume":"29","author":"GA Nichols","year":"2007","unstructured":"Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29(8):1761\u201370.","journal-title":"Clin Ther"},{"issue":"3 Suppl","key":"6817_CR7","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association\u2019s Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58\u201371.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"6817_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2015.06.049","volume":"242","author":"J Stock","year":"2015","unstructured":"Stock J. Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group. Atherosclerosis. 2015;242(1):346\u201350.","journal-title":"Atherosclerosis"},{"issue":"1","key":"6817_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10557-018-6775-0","volume":"32","author":"TN Harrison","year":"2018","unstructured":"Harrison TN, Hsu JY, Rosenson RS, Levitan EB, Muntner P, Cheetham TC, et al. Unmet patient need in statin intolerance: the clinical characteristics and management. Cardiovasc Drugs Ther. 2018;32(1):29\u201336.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6817_CR10","doi-asserted-by":"crossref","unstructured":"Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, et al. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018","DOI":"10.1007\/s40256-017-0259-7"},{"issue":"17","key":"6817_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"issue":"25","key":"6817_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"5","key":"6817_CR13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1742-1241.2003.tb10508.x","volume":"57","author":"RH Knopp","year":"2003","unstructured":"Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003;57(5):363\u20138.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"6817_CR14","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","volume":"166","author":"DM Kusters","year":"2015","unstructured":"Kusters DM, Caceres M, Coll M, Cuffie C, Gagne C, Jacobson MS, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166(6):1377\u201384 e1\u20133.","journal-title":"J Pediatr"},{"issue":"23","key":"6817_CR15","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497\u2013506.","journal-title":"JAMA"},{"issue":"23","key":"6817_CR16","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"6817_CR17","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20139.","journal-title":"N Engl J Med"},{"key":"6817_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","volume":"2","author":"MJ Koren","year":"2017","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2:598\u2013607.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"6817_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","volume":"57","author":"S Kasichayanula","year":"2018","unstructured":"Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018;57(7):769\u201379.","journal-title":"Clin Pharmacokinet"},{"key":"6817_CR20","doi-asserted-by":"crossref","unstructured":"Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, et al. Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications. J Cardiovasc Pharmacol Ther 2018:1074248418774043.","DOI":"10.1177\/1074248418774043"},{"issue":"6","key":"6817_CR21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"8","key":"6817_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","volume":"117","author":"DJ Blom","year":"2015","unstructured":"Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res. 2015;117(8):731\u201341.","journal-title":"Circ Res"},{"issue":"11","key":"6817_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"MC Serban","year":"2017","unstructured":"Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"6817_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M16-0838","volume":"167","author":"H Zhang","year":"2017","unstructured":"Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167(4):221\u20137.","journal-title":"Ann Intern Med"},{"issue":"6","key":"6817_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"6817_CR26","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","volume":"70","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70(10):1290\u2013301.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6817_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/clc.22535","volume":"39","author":"SR Gandra","year":"2016","unstructured":"Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39(6):313\u201320.","journal-title":"Clin Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6817-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6817-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6817-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T03:39:49Z","timestamp":1693798789000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6817-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["6817"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6817-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"2 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"L.C. has conducted research with Amgen and Esperion, has been a consultant for Amgen, and has been an unpaid consultant for Lilly. R.D. is a former employee of Amgen Inc. and a current employee and stockholder of Esperion. E.S.G.S. has received lecture fees for institution from Amgen, Sanofi, Chiesi, Novartis, and Ionis\/Akcea. E.A.S. has received consultancy and expert witness fees from Amgen, and consultancy fees from The Medicines Company, AstraZeneca, Moderna, CVS\/Caremark, and Gemphire. D.S. has received research support from Amgen, Merck, and Amarin; advisory board fees from Amgen, Merck, Abbott\/Mylan, and Sanofi; and modest honoraria for educational programs from Abbott\/Mylan and AbbVie. A.R. and R.S. are employees of Amgen and hold Amgen stock\/stock options. R.S. is an inventor on at least one pending patent involving evolocumab. A.F. is a contractor for Amgen Inc. R.S.R. has received research support for institution from Akcea, Amgen, AstraZeneca, The Medicines Company, Regeneron, and Sanofi; has served on advisory boards for Akcea, Amgen, CVS Caremark, Regeneron, and Sanofi; has received honoraria from Akcea, Kowa, and Pfizer; and has received royalties from UpToDate, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}